Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

ORAL Strategy investigators, Anna Mihailova (Member of the Working Group)

Research output: Contribution to journalArticlepeer-review

169 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences